Aarti Sawant‐Basak
AstraZeneca (South Korea)(KR)AstraZeneca (Brazil)(BR)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Receptor Mechanisms and Signaling, Tryptophan and brain disorders, Pharmacological Effects and Toxicity Studies, Neuropeptides and Animal Physiology
Most-Cited Works
- → Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746(2016)67 cited
- → Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors(2011)59 cited
- → The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations(2012)57 cited
- → Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans(2011)42 cited
- → Identification of Multiple 5-HT4Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease(2012)42 cited
- → Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology(2011)36 cited
- → Emerging Models of Drug Metabolism, Transporters, and Toxicity(2018)26 cited
- → Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects(2016)23 cited
- → Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics(2012)20 cited
- → Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments(2017)20 cited